Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia
Medical Health News,
Program Follows Successful Completion of Phase III Program in Mydriasis NEW YORK, June 04, 2019 (GLOBE NEWSWIRE) -- Eyenovia…
Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia
Morning Star,
(GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline…
Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia
NASDAQ,
(GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline…
Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia
Yahoo! Finance USA,
(GLOBE NEWSWIRE) -- Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of…
Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia
Biospace,
– Eyenovia Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose…
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
BioTech Gate,
On track to initiate Phase III trial in H1 2019 NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc.
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
TMCnet.com,
NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical…
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
NASDAQ,
On track to initiate Phase III trial in H1 2019 NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc.
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
Benzinga,
NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company…
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
Biospace,
–Eyenovia Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose…